Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for fetal neuroprotection in severe fetal growth restriction
ACTRN12617001515381Phase 3Active, not recruiting
- Sponsor
- Monash Health
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in intrauterine growth restriction (IUGR) comparing Melatonin with Placebo (2 arms). Primary endpoint: Neurodevelopmental outcomes. Started May 2019; status: active, not recruiting.
02
Drugs
melatonin
03
Conditions
intrauterine growth restriction (IUGR)
Beyond the preview
Go deeper on ACTRN12617001515381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001515381.